Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
Discontinued
Reference number: GID-TA10522
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Inebilizumab within its marketing authorisation for reducing the risk of attacks and worsening of disability in patients with neuromyelitis optica spectrum disorders.
Please note that following advice received from the company, further information regarding the timelines for this appraisal will be available in due course.